|
|
International Isotopes Inc (INIS) |
|
Price: $0.0470
$0.01 
11.905%
|
| Day's High:
| $0.047
| Week Perf:
| 23.68 %
|
| Day's Low: |
$ 0.04 |
30 Day Perf: |
34.29 % |
| Volume (M): |
143 |
52 Wk High: |
$ 0.05 |
| Volume (M$): |
$ 7 |
52 Wk Avg: |
$0.04 |
| Open: |
$0.04 |
52 Wk Low: |
$0.02 |
|
|
| Market Capitalization (Millions $) |
25 |
| Shares
Outstanding (Millions) |
523 |
| Employees |
40 |
| Revenues (TTM) (Millions $) |
12 |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
International Isotopes Inc
International Isotopes Inc is a publicly traded company engaged in the production and sales of nuclear medicine products and radioactive materials. They operate a facility for the processing and fabrication of radioisotopes used in various medical applications such as cancer treatment and diagnostic imaging. The company also provides radiological services, including decontamination and waste management solutions. International Isotopes Inc aims to meet the increasing demand for reliable and safe sources of isotopes and radiation-based products in the global market.
Company Address: 4137 Commerce Circle Idaho Falls 83401 ID
Company Phone Number: 524-5300 Stock Exchange / Ticker: INIS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| International Isotopes Inc
As a financial analyst for the CSIMarket.com, I am here to interpret the recent financial results of International Isotopes Inc (INIS) for the January to March 31, 2024 period. According to the data, INIS reached zero gain of $0.00 per share compared to $0.00 a year prior and $0.00 per share from the preceding reporting season. This indicates a stagnant performance in terms of earnings per share.
On the revenue front, there was a decrease of -7.232% to $2.87 million from $3.09 million in the same reporting season a year prior. However, sequentially the revenue advanced by 7.986% from $2.65 million. This fluctuation in revenue numbers may point towards the company's varying performance in different quarters.
|
| International Isotopes Inc
International Isotopes Inc, a leading player in the isotopes industry, recently released its financial results for the fourth quarter of 2023. The company reported balanced books with earnings of $0.00 per share, which remained steady compared to the previous year. This shows stability in the company's financial performance over the past year.
However, the revenue for the quarter took a hit, declining by 15.753% to $2.65 million from $3.15 million in the same period last year. Sequentially, the revenue decreased by 4.96% from $2.79 million. This decline is certainly a cause for concern, and International Isotopes Inc needs to address the underlying reasons behind this slump.
|
| International Isotopes Inc
International Isotopes Inc, an Electronic Instruments & Controls company, experienced a moderate increase in revenue, reaching break-even on a 0.122% rise to $2.79 million in the financial period ending September 30, 2023, compared to the same period the previous year.
During this time, many corporations in the Electronic Instruments & Controls industry struggled with receding transactions and declining revenue. However, International Isotopes Inc managed to flourish in the third quarter of 2023. In comparison to the preceding reporting period, their revenue decreased by -1.757% from $2.84 million. The company reported a net shortfall of $-0.349 million, an improvement from the deficit of $-0.569 million in the same period a year ago.
|
| International Isotopes Inc
Financial News Report:
International Isotopes Inc (INIS) Reports Revenue Growth but Earnings Remain Flat
In the most recent fiscal period, International Isotopes Inc (INIS) reported notable revenue growth of 16.749% to $2.84 million. However, earnings remained unaffected at $0.00 per share, year on year. Despite the stagnant earnings, INIS has outperformed its industry peers in the Electronic Instruments & Controls industry, which only saw a 1.35% revenue advance during the same period.
Moving on to the preceding quarter, INIS saw a decline in revenue of -7.992% from $3.09 million. This downturn could have contributed to the flat earnings reported for the most recent fiscal period. It is worth noting that during the April to June 2023 fiscal period, International Isotopes Inc reported a net loss of $-0.263 million, an improvement compared to the deficit of $-0.272 million in the comparable quarter a year ago.
|
| International Isotopes Inc
International Isotopes Inc, a company specializing in the production and sale of radioisotopes and nuclear medicine products, released their financial results for the period ending March 31, 2023. During this period, the company managed to balance their books, recording a net income of $0.00 per share, which is similar to the previous year's result and the preceding financial reporting period.
When it comes to revenue, International Isotopes Inc saw significant growth during this period, with a 10.048% increase to $3.09 million in comparison to the $2.81 million recorded during the previous financial reporting period. However, the company also experienced a sequential decrease in revenue of -1.934%, with the amount dropping from $3.15 million.
|
| Per Share |
Current |
| Earnings (TTM) |
-0 $ |
| Revenues (TTM) |
0.02 $
|
| Cash Flow (TTM) |
0 $ |
| Cash |
0 $
|
| Book Value |
0.01 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0 $
|
| Revenues (TTM) |
0.02 $ |
| Cash Flow (TTM) |
0 $ |
| Cash |
0 $
|
| Book Value |
0.01 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Theranostics Products |
|
 63.29 % |
of total Revenue |
| Cobalt Products |
|
23.62 % |
of total Revenue |
| Nuclear Medicine Products |
|
26.86 % |
of total Revenue |
| UNITED STATES |
|
102.9 % |
of total Revenue |
| UNITED STATES Theranostics Products |
|
60.64 % |
of total Revenue |
| UNITED STATES Cobalt Products |
|
23.62 % |
of total Revenue |
| UNITED STATES Nuclear Medicine Products |
|
18.64 % |
of total Revenue |
| Non-US |
|
10.87 % |
of total Revenue |
| Non-US Theranostics Products |
|
2.66 % |
of total Revenue |
| Non-US Nuclear Medicine Products |
|
8.21 % |
of total Revenue |
|
|
